BNTX EQUITY Biological Products, (No Diagnostic Substances) 2027 Quantitative Forecast

BioNTech SE American Depositary Share (BNTX) Stock Price Prediction 2027

Multi-horizon algorithmic price targets, Wall Street consensus calibration, reverse-DCF growth expectations & options volatility valuation

$80.96
$-0.42 (-0.52%)
Market Close: Nov 20, 2026
1-Year Base Target
$112.27 +38.7%
Constant-P/E algorithmic trajectory
Wall St. Consensus
$112.27 Bull $140
Institutional analyst mean target
Risk-Adjusted Consensus Fair Value
$95.43 +17.9% Undervalued
Forward P/E -17.1x • PEG 0.05
AI Quant Stance
HOLD 44/100
RSI 31.7 • MACD Bearish • Downtrend

Executive Forecast Synopsis (2027)

Synthesized fundamental, multiple & technical thesis for BNTX

AI Research Note

BNTX Price Forecast 2027: Our AI models project that BNTX stock will rise to approximately $112.27 by 2027. This represents a potential 38.7% growth from the current trading price of $80.96. The overall market sentiment for BNTX is currently bullish, based on a combination of proprietary technical signals and fundamental analysis.

Fundamental Analysis: Trading with its most recent quarterly earnings growing by -43.2%. BNTX shows a complex fundamental profile. Our model evaluates these metrics alongside sector peers and historical performance to derive the 2027 price target. If the company exceeds its current growth projections, there may be further upside beyond our base case scenario.

Technical Outlook: The stock is technically in a downtrend phase. The Relative Strength Index (RSI) is currently 31.7, which suggests the stock is trading in a neutral range. Traders should monitor key support and resistance levels closely, as a breakout or breakdown from current price consolidation will be the primary catalyst for the stock reaching the 2027 predicted target.

Quant Signal & Technical Posture

Composite equity rating reconciled with 1-year target trajectory

Score: 44.1/100
Composite Equity Stance
HOLD (Quant Score 44/100) — HOLD (+38.7% 1Y Target Upside)
Active Technical & Price Action Triggers
  • Volume showing distribution (CMF: -0.1767)
  • Recent pattern: Doji - Indecision pattern
  • Price near support at $80.74
MACD Regime: Bearish
Volume Tape: Distribution

BNTX Trajectory & Forecast Curve

Projected price curve from spot ($80.96) across 30D–3Y horizons

Term Structure of Price Targets

Constant-multiple earnings trajectory model

30D – 3Y
Horizon Target Price Implied Return
30 Days Near-Term $83.47 +3.1%
90 Days 1 Quarter $88.79 +9.7%
6 Months Medium-Term $96.62 +19.3%
1 Year Base Model $112.27 +38.7%
Wall Street 12M Consensus Target: $112.27

1-Year Scenario Distribution (Bull / Base / Bear)

Probability-weighted regime outcomes around the 12-month forecast horizon

Regime Matrix
Bull Case 30% Prob
$140.34 +73.3%

Best case scenario if strong fundamentals and market conditions align

Base Case 50% Prob
$112.27 +38.7%

Expected scenario based on current growth trajectory

Bear Case 20% Prob
$78.59 -2.9%

Downside scenario if market headwinds or disappointing results

Reverse-DCF Implied Growth, Supply-Chain Moat & R&D Velocity

Proprietary deep-tech expectations gap, supply-chain bottleneck scoring & patent/filing velocity

Deep-Tech & Valuation Intelligence
Supply-Chain Moat & Nx Model Bottleneck 5/10
Moat: None • Position: Drug Discovery Biotech (drug_design)
1Y Modeled
x
3Y Modeled
x
5Y Thesis Adj
x
R&D & Commercialization Velocity
90D Commercialization Mentions: 47 disclosures
Commercialization Themes:
mRNA Therapeutics (47)

Fair Value & Core Fundamentals

PEG-adjusted intrinsic valuation & balance-sheet multiples

+17.9% Undervalued
Risk-Adjusted Consensus Fair Value: $95.43
Spot: $80.96

Risk-Adjusted Consensus Fair Value (85% of Wall Street target) indicates BNTX trades at a discount to its forward earnings growth trajectory (17.9% implied margin of safety).

PEG Ratio
0.05
Attractive (<1.0)
Implied Fair P/E
-20.2x
Model Growth 38.7%
Forward P/E
-17.13x
P/S Ratio (TTM)
8.34x
Rev Growth (YoY)
-15.1%
EPS Growth (YoY)
-43.2%
Market Cap
$20,176M
52-Week High
$124.00
52-Week Low
$79.52

Technicals & Institutional Money Flow

Momentum oscillators, volume accumulation & key price levels

Distribution
Volume Tape: Distribution

Volume-weighted price action shows near-term supply/distribution pressure; watch support levels for stabilization.

RSI (14-Day)
31.7
Neutral
MACD Signal
Bearish
Primary Trend
Downtrend
Chaikin Money Flow
-0.177
Money Flow Index
24.7
200-Day SMA
$96.09

Frequently Asked Questions (BNTX 2027 Outlook)

What is the BNTX stock price prediction for 2027?

Based on our AI analysis, BNTX is predicted to reach $112.27 by 2027, representing a potential 38.7% increase from the current price of $80.96.

Is BNTX stock a good buy right now?

Our analysis rates BNTX as a HOLD (AI Quant Score 44.1/100) based on current technical and fundamental indicators. With a projected 38.7% upside in our 1-year constant-P/E model, investors should consider their risk tolerance and investment horizon.

What is BNTX 52-week high and low?

BNTX has a 52-week high of $124.00 and a 52-week low of $79.52. The stock is currently trading 34.7% below its 52-week high.

What is the technical analysis for BNTX?

BNTX is currently in a downtrend trend. The RSI of 31.7 indicates the stock is trading in neutral territory. Traders should monitor support and resistance levels for potential entry points.

Quantitative Research Disclaimer: Price predictions, reverse-DCF expectations, and options volatility strategies are generated algorithmically from historical financial data, analyst consensus estimates, and live options chains. They are provided strictly for informational and research purposes and do not constitute investment advice. Always conduct independent due diligence before executing equity or derivative transactions.